Neurodegeneration Biomarkers Predict MCI Onset

Blood-based biomarkers of amyloid and tau predict Alzheimer’s disease (AD) dementia, but the role in predicting mild cognitive impairment (MCI) is less understood. Researchers conducted a prospective study to examine if blood biomarkers of amyloid (Aβ42 /Aβ40 ratio), tau (p-tau181), neurodegeneration (NfL), and neuroinflammation (glial fibrillary acidic protein [GFAP], YKL40, soluble triggering receptor expressed on myeloid cells 2 [sTREM2]) predict the onset of in people with MCI who were cognitively normal at the start.